NorthWest Biotherapeutics Inc (NWBO)

[Red_Right_Hand]

8K filed 5/2:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001072379/000110465924056424/tm2413348d1_8k.htm

Item 1.01. Entry into a Material Definitive Agreement.
Loan Entered Into

On April 26, 2024, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000. The Loan Agreement has a maturity of 22 months. Repayments do not start until December 26, 2024.

Following December 26, 2024, the Loan Agreement will be amortized in 14 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest. Interest on the Loan Agreement accrues at a rate of 8% per annum, and the Loan Agreement includes an original issue discount of ten percent. The Loan Agreement allows pre-payment at any time at the Company’s election. If the Company elects to pre-pay, the pre-payment would include a 10% charge. The Loan Agreement contains customary default provisions, including for potential acceleration.

The funds will be used for the Company’s ongoing business operations, including beginning initial construction works for the first grade C lab in the Company’s Sawston, UK facility, ordering certain initial long lead-time equipment for the first grade C lab, and facility preparations for delivery of the initial GMP units of the Flaskworks system.

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001072379/000110465924056424/tm2413348d1_8k.htm